NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $103.77 +1.20 (+1.17 %) (As of 03/20/2019 07:24 AM ET)Previous Close$102.57Today's Range$101.43 - $104.6952-Week Range$64.08 - $127.77Volume243,266 shsAverage Volume248,121 shsMarket Capitalization$2.02 billionP/E Ratio29.82Dividend YieldN/ABeta1.39 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. Receive ENTA News and Ratings via Email Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA Previous Symbol CUSIPN/A CIK1177648 Webwww.enanta.com Phone617-607-0800Debt Debt-to-Equity RatioN/A Current Ratio18.71 Quick Ratio18.71Price-To-Earnings Trailing P/E Ratio29.82 Forward P/E Ratio68.72 P/E GrowthN/A Sales & Book Value Annual Sales$206.63 million Price / Sales9.76 Cash Flow$3.8448 per share Price / Cash Flow26.99 Book Value$20.32 per share Price / Book5.11Profitability EPS (Most Recent Fiscal Year)$3.48 Net Income$71.95 million Net Margins36.19% Return on Equity22.78% Return on Assets21.54%Miscellaneous EmployeesN/A Outstanding Shares19,440,000Market Cap$2.02 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Wednesday, February, 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.46 by $0.21. The biotechnology company had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. Enanta Pharmaceuticals's quarterly revenue was up 83.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 earnings per share. View Enanta Pharmaceuticals' Earnings History. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals. What price target have analysts set for ENTA? 6 equities research analysts have issued twelve-month price targets for Enanta Pharmaceuticals' shares. Their predictions range from $80.00 to $133.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $102.60 in the next year. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Enanta Pharmaceuticals. What is the consensus analysts' recommendation for Enanta Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals. Has Enanta Pharmaceuticals been receiving favorable news coverage? Media headlines about ENTA stock have been trending positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Catalent (CTLT), Nektar Therapeutics (NKTR), Ascendis Pharma A/S (ASND), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY) and United Therapeutics (UTHR). What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), NVIDIA (NVDA), Zoetis (ZTS), Intercept Pharmaceuticals (ICPT), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Dollar Tree (DLTR), Celgene (CELG), Micron Technology (MU) and Mastercard (MA). Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the folowing people: Dr. Jay R. Luly, Pres, CEO & Director (Age 63)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53) Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.24%), First Manhattan Co. (3.50%), Dimensional Fund Advisors LP (3.21%), Krensavage Asset Management LLC (2.76%), Krensavage Asset Management LLC (2.75%) and Acadian Asset Management LLC (1.79%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals. Which major investors are selling Enanta Pharmaceuticals stock? ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, FMR LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co. and Barclays PLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals. Which major investors are buying Enanta Pharmaceuticals stock? ENTA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Citigroup Inc., Candriam Luxembourg S.C.A., Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Millennium Management LLC and KBC Group NV. View Insider Buying and Selling for Enanta Pharmaceuticals. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $103.77. How big of a company is Enanta Pharmaceuticals? Enanta Pharmaceuticals has a market capitalization of $2.02 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. What is Enanta Pharmaceuticals' official website? The official website for Enanta Pharmaceuticals is http://www.enanta.com. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected] MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 236 (Vote Outperform)Underperform Votes: 266 (Vote Underperform)Total Votes: 502MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What causes a recession?